| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.
|
J Acquir Immune Defic Syndr
|
2007
|
4.30
|
|
2
|
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature.
|
J Acquir Immune Defic Syndr
|
2002
|
3.55
|
|
3
|
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
|
J Infect Dis
|
2004
|
2.21
|
|
4
|
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
|
AIDS
|
2011
|
2.08
|
|
5
|
The extraordinary ligand binding properties of human serum albumin.
|
IUBMB Life
|
2005
|
2.00
|
|
6
|
Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations.
|
Retrovirology
|
2009
|
1.99
|
|
7
|
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.
|
J Antimicrob Chemother
|
2007
|
1.89
|
|
8
|
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.
|
J Neurovirol
|
2005
|
1.87
|
|
9
|
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
|
J Acquir Immune Defic Syndr
|
2009
|
1.81
|
|
10
|
Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART.
|
AIDS Res Hum Retroviruses
|
2005
|
1.52
|
|
11
|
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
|
J Infect Dis
|
2003
|
1.47
|
|
12
|
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
|
AIDS Res Hum Retroviruses
|
2002
|
1.45
|
|
13
|
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2006
|
1.41
|
|
14
|
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
|
AIDS
|
2005
|
1.37
|
|
15
|
Neurocognitive performance and quality of life in patients with HIV infection.
|
AIDS Res Hum Retroviruses
|
2003
|
1.29
|
|
16
|
Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
1.21
|
|
17
|
Leishmania infantum leishmaniasis in corticosteroid--treated patients.
|
BMC Infect Dis
|
2006
|
1.19
|
|
18
|
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
|
Curr HIV Res
|
2009
|
1.12
|
|
19
|
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
|
AIDS
|
2003
|
1.11
|
|
20
|
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
|
J Antimicrob Chemother
|
2006
|
1.11
|
|
21
|
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.
|
BMC Infect Dis
|
2012
|
1.10
|
|
22
|
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
|
New Microbiol
|
2012
|
1.10
|
|
23
|
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
|
J Infect Dis
|
2012
|
1.09
|
|
24
|
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
|
Antivir Ther
|
2004
|
1.07
|
|
25
|
Varicella zoster virus infection presenting as isolated diplopia: a case report.
|
BMC Infect Dis
|
2013
|
1.04
|
|
26
|
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
|
J Acquir Immune Defic Syndr
|
2012
|
1.04
|
|
27
|
Use of massive parallel pyrosequencing for near full-length characterization of a unique HIV Type 1 BF recombinant associated with a fatal primary infection.
|
AIDS Res Hum Retroviruses
|
2009
|
1.04
|
|
28
|
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
|
J Acquir Immune Defic Syndr
|
2010
|
1.03
|
|
29
|
Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa.
|
Infect Genet Evol
|
2005
|
1.03
|
|
30
|
Eosinophilic meningitis in a returned traveler from Santo Domingo: case report and review.
|
J Travel Med
|
2007
|
1.02
|
|
31
|
Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique.
|
Clin Infect Dis
|
2008
|
1.01
|
|
32
|
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
|
Antivir Ther
|
2006
|
0.98
|
|
33
|
Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review.
|
Int J Infect Dis
|
2009
|
0.98
|
|
34
|
Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection.
|
AIDS
|
2011
|
0.98
|
|
35
|
Binding of anti-HIV drugs to human serum albumin.
|
IUBMB Life
|
2004
|
0.97
|
|
36
|
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
|
Vaccine
|
2009
|
0.97
|
|
37
|
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
|
Curr HIV Res
|
2008
|
0.97
|
|
38
|
The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
|
AIDS
|
2008
|
0.95
|
|
39
|
The preventive phase I trial with the HIV-1 Tat-based vaccine.
|
Vaccine
|
2009
|
0.95
|
|
40
|
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
|
Clin Infect Dis
|
2004
|
0.94
|
|
41
|
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
|
J Med Virol
|
2006
|
0.94
|
|
42
|
Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.
|
AIDS
|
2010
|
0.93
|
|
43
|
Expansion of pre-terminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption.
|
AIDS
|
2002
|
0.92
|
|
44
|
Monophyletic outbreak of Hepatitis A involving HIV-infected men who have sex with men, Rome, Italy 2008-2009.
|
J Clin Virol
|
2012
|
0.92
|
|
45
|
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
|
J Infect Dis
|
2008
|
0.91
|
|
46
|
Interferon may prevent HIV viral rebound after HAART interruption in HIV patients.
|
J Interferon Cytokine Res
|
2008
|
0.91
|
|
47
|
Dynamics of NRTI resistance mutations during therapy interruption.
|
AIDS Res Hum Retroviruses
|
2009
|
0.91
|
|
48
|
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.
|
J Antimicrob Chemother
|
2012
|
0.89
|
|
49
|
Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine.
|
Malar J
|
2012
|
0.89
|
|
50
|
Implementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings.
|
Eur J Pediatr
|
2007
|
0.89
|
|
51
|
Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.
|
J Clin Microbiol
|
2002
|
0.87
|
|
52
|
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
|
AIDS Res Hum Retroviruses
|
2012
|
0.86
|
|
53
|
V gamma 9V delta 2 T-cell anergy and complementarity-determining region 3-specific depletion during paroxysm of nonendemic malaria infection.
|
Infect Immun
|
2003
|
0.86
|
|
54
|
Highly active antiretroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naive HIV+ patients with severe chronic infection.
|
J Acquir Immune Defic Syndr
|
2004
|
0.85
|
|
55
|
Ultra-deep sequencing reveals hidden HIV-1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption.
|
J Med Virol
|
2012
|
0.85
|
|
56
|
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
|
J Antimicrob Chemother
|
2011
|
0.85
|
|
57
|
Diagnostic difficulties of Lactobacillus casei bacteraemia in immunocompetent patients: a case report.
|
J Med Case Rep
|
2008
|
0.84
|
|
58
|
A rare case of severe myopathy associated with etravirine use.
|
AIDS
|
2010
|
0.84
|
|
59
|
Impact of pre-therapy viral load on virological response to modern first-line HAART.
|
Antivir Ther
|
2013
|
0.84
|
|
60
|
Disseminated cryptococcosis in an HIV-negative patient.
|
Int J Infect Dis
|
2008
|
0.84
|
|
61
|
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
|
Antivir Ther
|
2011
|
0.84
|
|
62
|
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.84
|
|
63
|
Total hip replacement infected with Mycobacterium tuberculosis complicated by Addison disease and psoas muscle abscess: a case report.
|
J Med Case Rep
|
2012
|
0.84
|
|
64
|
Plasmodium falciparum multiple infections, disease severity and host characteristics in malaria affected travellers returning from Africa.
|
Travel Med Infect Dis
|
2008
|
0.83
|
|
65
|
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
|
HIV Clin Trials
|
2012
|
0.83
|
|
66
|
Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent.
|
AIDS
|
2009
|
0.83
|
|
67
|
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
|
AIDS Patient Care STDS
|
2008
|
0.83
|
|
68
|
Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV.
|
IUBMB Life
|
2009
|
0.82
|
|
69
|
Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection.
|
J Infect Dis
|
2003
|
0.82
|
|
70
|
Renal complications in HIV disease: between present and future.
|
AIDS Rev
|
2012
|
0.81
|
|
71
|
Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.81
|
|
72
|
HIV-1 DNA burden dynamics in CD4 T cells and monocytes in patients undergoing a transient therapy interruption.
|
J Med Virol
|
2004
|
0.81
|
|
73
|
Decrease of methicillin resistant Staphylococcus aureus prevalence after introduction of a surgical antibiotic prophylaxis protocol in an Italian hospital.
|
New Microbiol
|
2008
|
0.81
|
|
74
|
High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy.
|
AIDS
|
2002
|
0.81
|
|
75
|
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART.
|
AIDS Res Hum Retroviruses
|
2008
|
0.80
|
|
76
|
Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.
|
Int Immunopharmacol
|
2013
|
0.80
|
|
77
|
Historical resistance profile helps to predict salvage failure.
|
Antivir Ther
|
2009
|
0.80
|
|
78
|
Molecular diagnosis and species identification of imported malaria in returning travellers in Italy.
|
Diagn Microbiol Infect Dis
|
2011
|
0.79
|
|
79
|
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
|
Antimicrob Agents Chemother
|
2009
|
0.79
|
|
80
|
The V118I mutation as a marker of advanced HIV infection and disease progression.
|
Antivir Ther
|
2007
|
0.79
|
|
81
|
Managing patients with sexual transmission of drug-resistant HIV.
|
Sex Health
|
2005
|
0.79
|
|
82
|
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
|
New Microbiol
|
2006
|
0.79
|
|
83
|
HIV-related pneumococcal lung disease: does highly active antiretroviral therapy or bacteremia modify radiologic appearance?
|
AIDS Patient Care STDS
|
2008
|
0.79
|
|
84
|
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.
|
Malar J
|
2011
|
0.78
|
|
85
|
A case of pulmonary tuberculosis presenting as diffuse alveolar haemorrhage: is there a role for anticardiolipin antibodies?
|
BMC Infect Dis
|
2010
|
0.78
|
|
86
|
Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: what is the clinical impact of the quasispecies distribution?
|
J Infect Dis
|
2011
|
0.78
|
|
87
|
Therapeutic drug monitoring in the management of HIV-infected patients.
|
Curr Med Chem
|
2008
|
0.78
|
|
88
|
[DREAM project early results (drug resources enhancement against AIDS in Mozambique)].
|
Ig Sanita Pubbl
|
2003
|
0.77
|
|
89
|
P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy.
|
Clin Diagn Lab Immunol
|
2003
|
0.77
|
|
90
|
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-associated polyclonal body cavity effusions that mimic primary effusion lymphomas.
|
Int J Cancer
|
2006
|
0.77
|
|
91
|
Dynamics of viral load rebound in plasma and semen after stopping effective antiretroviral therapy.
|
AIDS
|
2003
|
0.77
|
|
92
|
Gamma delta T cells and resolution of cytomegalovirus infection in an HIV/HCV coinfected patient after liver transplantation.
|
Transplantation
|
2005
|
0.77
|
|
93
|
Antiretroviral therapeutic drug monitoring in HIV-infected pregnant women: maternal immunovirological outcome at delivery and during the 18 month follow-up period.
|
Curr HIV Res
|
2012
|
0.77
|
|
94
|
Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
|
IUBMB Life
|
2012
|
0.76
|
|
95
|
Primary Toxoplasma gondii infection in a pregnant human immunodeficiency virus-infected woman.
|
Pediatr Infect Dis J
|
2002
|
0.76
|
|
96
|
Stopping antiretroviral therapy: role for therapeutic drug monitoring.
|
AIDS
|
2008
|
0.75
|
|
97
|
Tolerability of HAART in patients treated during acute HIV infection.
|
J Acquir Immune Defic Syndr
|
2010
|
0.75
|
|
98
|
Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.
|
AIDS
|
2008
|
0.75
|
|
99
|
Application of a molecular panel to demonstrate enterotropic virus shedding by healthy and human immunodeficiency virus-infected patients.
|
J Clin Microbiol
|
2005
|
0.75
|
|
100
|
Initial treatment of HIV-1 infection.
|
N Engl J Med
|
2008
|
0.75
|
|
101
|
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
|
Antivir Ther
|
2003
|
0.75
|
|
102
|
Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
|
Antivir Ther
|
2011
|
0.75
|
|
103
|
Myelomatous meningitis.
|
Eur J Haematol
|
2008
|
0.75
|
|
104
|
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
|
J Infect Dis
|
2006
|
0.75
|
|
105
|
Sonographic assessment of facial HIV-related lypoatrophy.
|
Dermatol Surg
|
2009
|
0.75
|
|
106
|
Is total lymphocyte count a reliable predictor of the CD4 lymphocyte cell count in resource-limited settings?
|
AIDS
|
2004
|
0.75
|
|
107
|
Anti-retrovirals and immunosuppressive drug interactions in a HIV-positive patient after liver transplantation.
|
Hepatogastroenterology
|
2004
|
0.75
|
|
108
|
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.
|
Scand J Infect Dis
|
2010
|
0.75
|
|
109
|
Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.
|
Curr HIV Res
|
2009
|
0.75
|
|
110
|
Primary effusion lymphoma in pleural and pericardial cavities with multiple solid nodal and extra-nodal involvement in a human immunodeficiency virus-positive patient.
|
Leuk Lymphoma
|
2007
|
0.75
|
|
111
|
Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.
|
IUBMB Life
|
2013
|
0.75
|